About this trial
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months.
Disqualifiers
co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.
Trial population
The study population consists of patients with chronic hepatitis B, Hepatitis B-related liver cirrhosis, and Hepatitis B-related acute-on-chronic liver failure
Trial design
Case-only
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Analysis of Methylomic Features in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure
Sponsors and contacts
Click on the lead sponsor to view all of their trials.